ストックスクリーナーアプリを入手
6.88
5.36%
0.35
プレマーケット:
7.28
0.40
+5.81%
前日終値:
$6.53
開ける：
$6.74
24時間の取引高:
12.70M
Relative Volume:
1.09
時価総額：
$2.69B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-4.4387
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
+8.86%
1か月 パフォーマンス:
+14.10%
6か月 パフォーマンス:
-9.59%
1年 パフォーマンス:
-28.56%
1日の値動き範囲:
$6.6641
$7.17
1週間の範囲:
$6.33
$7.17
52週間の値動き範囲:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.88 | 2.69B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
(RXRX) Investment Analysis - Stock Traders Daily
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - MSN
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Avanza Fonder AB Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion posts mid-stage data for lead asset - MSN
Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth - Insider Monkey
Blackrock’s 30 Most Important AI Stocks - Insider Monkey
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5%Still a Buy? - MarketBeat
Is Recursion Pharmaceuticals Stock a Buy? - MSN
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6%Should You Sell? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% HigherStill a Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8%What's Next? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.4% HigherTime to Buy? - MarketBeat
JPM25: Recursion $RXRXby AlbertRhymes with Haystack - substack.com
Why Recursion Pharmaceuticals Shares Are Dropping - TipRanks
Recursion Pharmaceuticals CEO sells shares worth $287,200 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells shares worth $287,200 - Investing.com India
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference - TipRanks
Recursion Pharmaceuticals: Betting Big On AI (NASDAQ:RXRX) - Seeking Alpha
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? - MSN
Long Term Trading Analysis for (RXRX) - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3%Time to Sell? - MarketBeat
Recursion: Investors Will Need To Be Patient (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.1% Following Analyst Downgrade - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA - Yahoo Finance
Recursion advances two cancer drug trials By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4%Should You Sell? - MarketBeat
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX) - MarketBeat
Recursion advances two cancer drug trials - Investing.com
RXRXRecursion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9%Time to Buy? - MarketBeat
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - Marketscreener.com
Recursion CEO to Present Pipeline and Platform Updates at JP Morgan Healthcare Conference - StockTitan
Iambic Therapeutics Taps Former Recursion CFO to Lead Financial Strategy and Development - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):